We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+42.04%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$128M
Cap. Flow
-$241M
Cap. Flow %
-12%
Top 10 Hldgs %
57.08%
Holding
77
New
4
Increased
7
Reduced
4
Closed
25

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$34.9M
2
GPCR icon
Structure Therapeutics
GPCR
+$22.9M
3
ARVN icon
Arvinas
ARVN
+$14.2M
4
TNGX icon
Tango Therapeutics
TNGX
+$9.33M
5
IMVT icon
Immunovant
IMVT
+$9.2M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$38.2M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$36.5M
3
VTYX
Ventyx Biosciences
VTYX
+$29.5M
4
FOLD
Amicus Therapeutics
FOLD
+$28.3M
5
EXEL icon
Exelixis
EXEL
+$25.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
$20.2M 1.01%
1,650,000
– –
RLAY icon
27
Relay Therapeutics
RLAY
$4.1B
$20M 1%
1,819,132
– –
ITOS
28
DELISTED
iTeos Therapeutics
ITOS
$19.8M 0.98%
1,804,058
– –
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
$17.4M 0.87%
1,189,943
– –
GPCR icon
30
Structure Therapeutics
GPCR
$3.41B
$16.3M 0.81%
+400,000
New +$22.9M
ORIC icon
31
Oric Pharmaceuticals
ORIC
$1.15B
$15.9M 0.79%
1,732,571
– –
IOVA icon
32
Iovance Biotherapeutics
IOVA
$1.82B
$11.4M 0.57%
1,400,000
-2,305,133
-62% -$12.1M
PRLD icon
33
Prelude Therapeutics
PRLD
$366M
$11M 0.55%
2,568,287
+73,269
+3% +$223K
RNAM
34
DELISTED
Avidity Biosciences
RNAM
$10.1M 0.51%
1,121,327
– –
NKTX icon
35
Nkarta
NKTX
$150M
$9.5M 0.47%
+1,440,000
New +$3.73M
ELVN icon
36
Enliven Therapeutics
ELVN
$3.92B
$8.94M 0.45%
646,058
– –
THRD
37
DELISTED
Third Harmonic Bio
THRD
$8.23M 0.41%
750,000
+229,583
+44% +$1.82M
ZNTL icon
38
Zentalis Pharmaceuticals
ZNTL
$337M
$6.82M 0.34%
450,000
– –
GERN icon
39
Geron
GERN
$828M
$6.33M 0.32%
3,000,000
– –
SYRE icon
40
Spyre Therapeutics
SYRE
$8.54B
$5.38M 0.27%
+250,000
New +$3.44M
OBIO icon
41
Orchestra BioMed
OBIO
$238M
$2.17M 0.11%
238,193
– –
FATE icon
42
Fate Therapeutics
FATE
$286M
$1.87M 0.09%
500,000
– –
KOD icon
43
Kodiak Sciences
KOD
$2.6B
$1.82M 0.09%
600,000
– –
BCAB icon
44
BioAtla
BCAB
$5.46M
$1.69M 0.08%
13,727
– –
BDTX icon
45
Black Diamond Therapeutics
BDTX
$96.8M
$1.42M 0.07%
506,000
– –
RAIN
46
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$1.38M 0.07%
1,152,212
– –
MIST icon
47
Milestone Pharmaceuticals
MIST
$138M
$516K 0.03%
309,007
– –
DBVT
48
DBV Technologies
DBVT
$799M
$476K 0.02%
50,000
-48,510
-49% -$470K
TARA icon
49
Protara Therapeutics
TARA
$220M
$392K 0.02%
209,227
– –
BCEL
50
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$291K 0.01%
2,202,333
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Boxer Capital held 77 positions worth $2.01B, up 6.8% from $1.88B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Boxer Capital withdrew a net $241M in Q4 2023, closing 25 positions and reducing 4 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $38.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Structure Therapeutics worth $16.3M.

  • Boxer Capital's largest Q4 2023 buy was Structure Therapeutics: 400,000 shares worth $16.3M.
  • Boxer Capital added most to argenx in Q4 2023, an estimated $34.9M increase.
  • Boxer Capital's biggest Q4 2023 reduction was Iovance Biotherapeutics, cutting an estimated $12.1M.
  • Boxer Capital fully exited Amylyx Pharmaceuticals in Q4 2023, selling an estimated $38.2M.
  • Boxer Capital's ten largest holdings make up 57% of its $2.01B portfolio in Q4 2023.
  • Boxer Capital opened 4 new positions and closed 25 in Q4 2023.
  • Boxer Capital's portfolio value rose 6.8% quarter-over-quarter to $2.01B.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.